HONG KONG, Dec 7 (Bernama) --
Aptorum Group Limited (“Aptorum”, or the “Company”), a Hong Kong based pharmaceutical company currently in the preclinical stage, dedicated to developing and commercializing therapeutic projects and diagnostic technologies to tackle unmet medical needs, today announced that on December 3, 2018, its registration statement on Form F-1, relating to a proposed initial public offering (“IPO” or the “Offering”) of its Class A Ordinary Shares, par value US$1.00 per share (the “Shares”), at a price to the public of $15.80 per share, for gross proceeds of a minimum of US$10 million and up to US$30 million, has been declared effective by the U.S. Securities and Exchange Commission (“SEC”). The Company is offering up to 1,898,734 Shares and up to 51,990 underwriter warrants while certain selling shareholders are offering up to 1,595,235 Shares (collectively, the “Registered Securities”). None of the gross proceeds will be used to purchase the selling shareholders’ securities. The Shares are expected to begin trading on The NASDAQ Global Market on December 18, 2018, under the symbol APM. This Offering is expected to close on or before December 12, 2018, subject to customary closing conditions.
The Offering will be sold on a best-efforts basis. Boustead Securities, LLC, China Renaissance Securities (HK) Limited, and AMTD Global Markets Limited are acting as Co-Underwriters for the Offering.
For the full text, click here